84832-01-9

Basic information

• Product Name: METHYL 2,6-DIFLUORO-3-NITROBENZOATE
• Synonyms: METHYL 2,6-DIFLUORO-3-NITROBENZOATE;Benzoic acid,2,6-difluoro-3-nitro-, methyl ester (Related Reference)
• CAS NO: 84832-01-9
• Molecular Formula: C₈H₅F₂NO₄
• Molecular Weight: 217.1264064
• Mol File: 84832-01-9.mol
• Article Data: 17

Chemical Properties

• Melting Point: 59.0 to 63.0 °C
• Boiling Point: 151°C/9mmHg(lit.)
• Flash Point: 146.315 °C
• Appearance: /Solid
• Density: 1.471 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 2,6-DIFLUORO-3-NITROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2,6-DIFLUORO-3-NITROBENZOATE(84832-01-9)
• EPA Substance Registry System: METHYL 2,6-DIFLUORO-3-NITROBENZOATE(84832-01-9)

Safety Data

• Hazardous Substances Data: 84832-01-9(Hazardous Substances Data)

Usage

General Description

Methyl 2,6-Difluoro-3-Nitrobenzoate is a molecular entity and organic compound. It falls under the category of organofluorines and aromatic esters. The properties of this compound are derived from the presence of nitro, ester, and fluoro substituents on its benzene ring. The empirical formula is C8H5F2NO4. As a chemical compound, it serves as a crucial component in the research and development field, particularly in the production and synthesis of other complex compounds in laboratories. Its usage, handling, and disposal should be done with caution as per regional rules and regulations due to the potential risks associated with its hazardous properties.

Upstream product

• 13671-00-6 methyl 2,6-difluorobenzoate 
• 385-00-2 2,6-difluorobenzoic acid 
• 67-56-1 methanol 
• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 

Downstream Products

• 125568-92-5 3,3'-dicarbomethoxy-2,2',4,4'-tetrafluoroazobenzene 
• 125568-85-6 methyl N-benzyl-3-amino-2,6-difluorobenzoate 
• 125568-98-1 2,2,3,3-tetramethyl-1-(4,6-difluoro-5-carbomethoxyphenyl)aziridine 
• 125568-79-8 methyl 3-azido-2,6-difluorobenzoate 
• 1160682-51-8 N-{[7-(3,5-difluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl}glycine 
• 1160685-63-1 methyl 7-(3-fluorophenyl)-6-(methyloxy)-2-{[(trifluoromethyl)sulfonyl]oxy}-5-quinoxalinecarboxylate 
• 1160684-83-2 Ethyl N-({2-[3,5-bis(methyloxy)phenyl]-6-hydroxy-5-quinoxalinyl}carbonyl)glycinate 
• 1160685-24-4 Ethyl N-{[2-(2,3-difluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl}glycinate 
• 1160685-64-2 methyl 2-(3,4-difluorophenyl)-7-(3-fluorophenyl)-6-(methyloxy)-5-quinoxalinecarboxylate 
• 1160682-91-6 7-Bromo-3-(4-cyclohexylphenyl)-6-hydroxy-5-quinoxalinecarboxylic acid 
• 1160683-60-2 N-{[6-hydroxy-2-phenyl-7-(2-pyridinyl)-5-quinoxalinyl]carbonyl}glycine 
• 1160684-97-8 N-{[6-hydroxy-3-phenyl-2-(propylamino)-5-quinoxalinyl]carbonyl}glycine 
• 1160685-39-1 ethyl N-{[6-hydroxy-3-phenyl-2-(1,3-thiazol-2-yl)-5-quinoxalinyl]carbonyl}glycinate 
• 1160685-98-2 ethyl N-[(7-bromo-6-hydroxy-2-oxo-3-phenyl-1,2-dihydro-5-quinoxalinyl)carbonyl]glycinate 

Relevant articles and documents

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

Denitrified purine compound and pharmaceutical composition, preparation method and application thereof

The invention relates to denitrified purine compound which has a structure as a following general formula 1, a preparation method of the denitrified purine compound, a pharmaceutical composition containing the denitrified compound and application of the denitrified compound. The compound has selective B-Raf V600E mutation cancer cell inhibition activity, so that the denitrified purine compound disclosed by the invention and the pharmaceutical composition of the denitrified purine compound can be applied to preparing medicine for treating tumor or cancer.

Protein kinase inhibitor and its composition and use thereof

The invention relates to compounds as shown in the general formula (I), pharmaceutical compositions containing the compounds, a method for treating diseases and disease symptoms related to abnormal activity of protein kinase by using the compounds, and medicinal use of the compounds.